These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33077645)

  • 1. V Region of IgG Controls the Molecular Properties of the Binding Site for Neonatal Fc Receptor.
    Rossini S; Noé R; Daventure V; Lecerf M; Justesen S; Dimitrov JD
    J Immunol; 2020 Nov; 205(10):2850-2860. PubMed ID: 33077645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational Destabilization of Immunoglobulin G Increases the Low pH Binding Affinity with the Neonatal Fc Receptor.
    Walters BT; Jensen PF; Larraillet V; Lin K; Patapoff T; Schlothauer T; Rand KD; Zhang J
    J Biol Chem; 2016 Jan; 291(4):1817-1825. PubMed ID: 26627822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Two-pronged Binding Mechanism of IgG to the Neonatal Fc Receptor Controls Complex Stability and IgG Serum Half-life.
    Jensen PF; Schoch A; Larraillet V; Hilger M; Schlothauer T; Emrich T; Rand KD
    Mol Cell Proteomics; 2017 Mar; 16(3):451-456. PubMed ID: 28062799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants.
    Raghavan M; Bonagura VR; Morrison SL; Bjorkman PJ
    Biochemistry; 1995 Nov; 34(45):14649-57. PubMed ID: 7578107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypes.
    Szikora B; Hiripi L; Bender B; Kacskovics I; Iliás A
    PLoS One; 2017; 12(9):e0185662. PubMed ID: 28957416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry.
    Jensen PF; Larraillet V; Schlothauer T; Kettenberger H; Hilger M; Rand KD
    Mol Cell Proteomics; 2015 Jan; 14(1):148-61. PubMed ID: 25378534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
    Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
    Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn.
    Reusch J; Andersen JT; Rant U; Schlothauer T
    MAbs; 2024; 16(1):2361585. PubMed ID: 38849969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
    Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
    J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport.
    Stapleton NM; Armstrong-Fisher SS; Andersen JT; van der Schoot CE; Porter C; Page KR; Falconer D; de Haas M; Williamson LM; Clark MR; Vidarsson G; Armour KL
    Mol Immunol; 2018 Mar; 95():1-9. PubMed ID: 29367080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen physiochemical properties allosterically effect the IgG Fc-region and Fc neonatal receptor affinity.
    Sun Y; Estevez A; Schlothauer T; Wecksler AT
    MAbs; 2020; 12(1):1802135. PubMed ID: 32795110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
    Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
    MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,).
    West AP; Bjorkman PJ
    Biochemistry; 2000 Aug; 39(32):9698-708. PubMed ID: 10933786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization.
    Foss S; Grevys A; Sand KMK; Bern M; Blundell P; Michaelsen TE; Pleass RJ; Sandlie I; Andersen JT
    J Control Release; 2016 Feb; 223():42-52. PubMed ID: 26718855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
    Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
    Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of IgG2 high molecular weight species on neonatal Fc receptor binding assays.
    Zhang Y; Mathur A; Maher G; Arroll T; Bailey R
    Anal Biochem; 2015 Nov; 489():25-31. PubMed ID: 26255698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).
    Dall'Acqua WF; Kiener PA; Wu H
    J Biol Chem; 2006 Aug; 281(33):23514-24. PubMed ID: 16793771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
    Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
    MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.